Zimmer Biomet Holdings Inc (NYSE:ZBH) CEO Bryan C. Hanson bought 410 shares of the firm’s stock in a transaction that occurred on Friday, August 31st. The shares were purchased at an average cost of $123.03 per share, for a total transaction of $50,442.30. Following the purchase, the chief executive officer now owns 25,487 shares in the company, valued at approximately $3,135,665.61. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

ZBH stock opened at $121.97 on Wednesday. The company has a current ratio of 2.41, a quick ratio of 1.25 and a debt-to-equity ratio of 0.78. The stock has a market capitalization of $25.16 billion, a price-to-earnings ratio of 15.19, a P/E/G ratio of 2.25 and a beta of 1.09. Zimmer Biomet Holdings Inc has a 1 year low of $104.28 and a 1 year high of $129.34.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Friday, July 27th. The medical equipment provider reported $1.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.88 by $0.04. The company had revenue of $2.01 billion for the quarter, compared to analyst estimates of $1.99 billion. Zimmer Biomet had a return on equity of 13.53% and a net margin of 21.67%. Zimmer Biomet’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter last year, the company earned $2.08 EPS. equities analysts forecast that Zimmer Biomet Holdings Inc will post 7.67 EPS for the current fiscal year.

A number of hedge funds have recently bought and sold shares of ZBH. JPMorgan Chase & Co. increased its holdings in shares of Zimmer Biomet by 4.8% in the 1st quarter. JPMorgan Chase & Co. now owns 9,826,738 shares of the medical equipment provider’s stock valued at $1,071,511,000 after acquiring an additional 450,979 shares during the last quarter. American Century Companies Inc. increased its holdings in shares of Zimmer Biomet by 5.5% in the 1st quarter. American Century Companies Inc. now owns 5,039,181 shares of the medical equipment provider’s stock valued at $549,472,000 after acquiring an additional 261,784 shares during the last quarter. Wells Fargo & Company MN increased its holdings in shares of Zimmer Biomet by 13.1% in the 1st quarter. Wells Fargo & Company MN now owns 2,312,443 shares of the medical equipment provider’s stock valued at $252,149,000 after acquiring an additional 268,068 shares during the last quarter. Ceredex Value Advisors LLC purchased a new position in shares of Zimmer Biomet in the 1st quarter valued at about $179,652,000. Finally, Neuberger Berman Group LLC increased its holdings in shares of Zimmer Biomet by 8.2% in the 1st quarter. Neuberger Berman Group LLC now owns 1,375,068 shares of the medical equipment provider’s stock valued at $149,937,000 after acquiring an additional 104,493 shares during the last quarter. 87.22% of the stock is currently owned by institutional investors.

Several equities analysts recently issued reports on the company. Argus lowered Zimmer Biomet from a “buy” rating to a “hold” rating in a research note on Friday, June 22nd. Piper Jaffray Companies increased their target price on Zimmer Biomet from $110.00 to $120.00 and gave the stock a “neutral” rating in a research note on Monday, July 30th. Zacks Investment Research lowered Zimmer Biomet from a “hold” rating to a “sell” rating in a research note on Monday, July 2nd. ValuEngine raised Zimmer Biomet from a “sell” rating to a “hold” rating in a research note on Wednesday, July 25th. Finally, Jefferies Financial Group increased their target price on Zimmer Biomet to $145.00 and gave the stock a “buy” rating in a research note on Monday, July 30th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and fifteen have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $135.10.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

Featured Article: Trading Strategy Methods and Types

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.